The most recently completed cardiovascular outcomes trial of a CETP inhibitor, the Heart Protection Study (HPS)3/Thrombolysis in Myocardial Infarction (TIMI)55–Evaluation of the Effects of Anacetrapib through Lipid Modification (REVEAL) trial, demonstrated that adding anacetrapib to intensive atorvastatin therapy for a median follow-up period of 4.1 years significantly reduced the primary endpoint of a first major coronary event (composite of coronary death, myocardial infarction, or coronary revascularization) by 9% compared to adding placebo [28]. The gene discussed is CETP; the disease is myocardial infarction.